Please login to the form below

Not currently logged in
Email:
Password:

Free cancer drugs for Thailand if changes made

According to local media reports, the Thai health minister has said that Swiss pharmaceutical company Novartis may provide the country with free cancer medicine, if the current drive for generic versions of patented drugs is halted.

According to local media reports, the Thai health minister has said that Swiss pharmaceutical company Novartis may provide the country with free cancer medicine, if the current drive for generic versions of patented drugs is halted.

Thailand is currently embroiled in an battle with global pharmaceutical companies over compulsory licences, which temporarily suspend patent protection.

The government has already issued compulsory licences to obtain generic versions of a heart drug and two HIV medicines.

In September 2007, the government announced it would also seek generic versions of four cancer drugs.

During talks with Novartis, health minister Mongkol Na Songkhla said the company had offered to provide its oncology product Gleevec/ Glivec (imatinib) for free, if Thailand halted its drive to expand its generic drug programme.

If a deal was reached, the government could provide unlimited amounts of the drug through its universal health care scheme, concluded Songkhla.

Per month, Imatinib currently costs up to THB 100,000 (USD 2,950).

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics